Proteomic analysis of short-term preload-induced eccentric cardiac hypertrophy

Belal A. Mohamed¹,²,³, Abdul R. Asif⁴†, Moritz Schnelle¹, Mohamed Qasim⁴,⁵, Sara Khadjeh¹,², Dawid Lbik¹,², Peter Schott¹, Gerd Hasenfuss¹,² and Karl Toischer¹,²,⁶*

Abstract

Background: Hemodynamic load leads to cardiac hypertrophy and heart failure. While afterload (pressure overload) induces concentric hypertrophy, elevation of preload (volume overload) yields eccentric hypertrophy and is associated with a better outcome. Here we analysed the proteomic pattern of mice subjected to short-term preload.

Methods and Results: Female FVB/N mice were subjected to aortocaval shunt-induced volume overload that leads to an eccentric hypertrophy (left ventricular weight/tibia length +31 %) with sustained systolic heart function at 1 week after operation. Two-dimensional gel electrophoresis (2-DE) followed by mass spectrometric analysis showed alteration in the expression of 25 protein spots representing 21 different proteins. 64 % of these protein spots were up-regulated and 36 % of the protein spots were consistently down-regulated. Interestingly, α-1-antitrypsin was down-regulated, indicating higher elastin degradation and possibly contributing to the early dilatation. In addition to contractile and mitochondrial proteins, polymerase I and transcript release factor protein (PTRF) was also up-regulated, possibly contributing to the preload-induced signal transduction.

Conclusions: Our findings reveal the proteomic changes of early-stage eccentric myocardial remodeling after volume overload. Induced expression of some of the respiratory chain enzymes suggests a metabolic shift towards an oxidative phosphorylation that might contribute to the favorable remodeling seen in early VO. Down-regulation of α-1-antitrypsin might contribute to extracellular matrix remodeling and left ventricular dilatation. We also identified PTRF as a potential signaling regulator of volume overload-induced cardiac hypertrophy.

Keywords: Aortocaval shunt, Preload, Eccentric hypertrophy, Heart failure

Background

In the heart, hemodynamic load is a critical regulator of myocardial function, gene expression and phenotype appearance [1]. Thereby two types of load can be differentiated, namely preload and afterload. Preload increases during diastolic filling and passively stretches cardiomyocytes. This results in immediate recruitment of contractile units and increased cardiac performance through the Frank-Starling mechanism. In addition, proteins such as titin and associated molecules are stretched with subsequent effects on myocardial elasticity and gene expression [2]. By electromechanical coupling, systolic force is generated by each cardiomyocyte to produce cardiac stroke work against the vascular resistance (afterload). During ejection preload declines again. Both preload and afterload influence load-dependent ion channels and intracellular ion concentrations [3], which in turn may also influence cardiac function and gene expression. A pathologically increased afterload occurs in patients with aortic stenosis or arterial hypertension, whereas an increase in preload occurs mainly in patients with mitral or aortic regurgitation. Afterload leads to a concentric hypertrophy with an increase in wall thickness and normal left ventricular volume, whereas preload leads to eccentric hypertrophy with normal wall thickness and an increase in the left ventricular volume.
From a hemodynamic point of view, afterload-mediated concentric hypertrophy was long considered beneficial because of stress compensation through increased wall thickness according to the law of Laplace [4]. In contrast, preload-mediated eccentric hypertrophy was considered maladaptive because of uncompensated wall stress. Previously we adjusted two in vivo models of hemodynamic load to compare the effects of mechanical load on the heart failure development. We used the transverse aortic constriction (TAC) as an afterload model and the aortocaval shunt (shunt) as a preload model and could show that preload has a more beneficial phenotype compared to afterload [5]. Afterload leads to an activation of CaMKII, which is involved in the progression of heart failure [6, 7]. Preload is associated with Akt activation without fibrosis, little apoptosis, better function, and lower mortality compared to afterload. Interestingly, B-type natriuretic peptide (Nppb), a hallmark for maladaptive remodeling of the LV, was not reactivated up to 7 days in our shunt model [5], which could also be proven in an in vitro model of loaded isolated rabbit muscle strips [8, 9]. Therefore, our current proteome study was performed at the same time point (1 week after shunt) to unravel the potential factors mediating the preload-induced favorable myocardial remodeling.

Methods

Animals

The investigation conforms to the Guide for the Care and Use of Laboratory Animals (NIH publication No. 85–23, revised 1996). The experiments were initiated on 8–10 week FVB/N wild-type female animals (Charles River, Sulzfeld, Germany) were used because of high mortality in male mice.

Aortocaval shunt operation (shunt)

Surgery was performed as described previously [5]. Briefly, mice were anesthetized using isoflurane insufflation. A longitudinal abdominal incision was made and the vessels were prepared. The aorta was clamped and punctured with a needle (23G) through the vena cava inferior. After removing the needle, the external hole in the aorta was closed by cyanoacrylate glue (Pattex, Düsseldorf, Germany). In successful shunt operations mixing of oxygenated blood from the abdominal aorta in the vena cava could be observed. The abdomen was then closed and the mice were kept on a heating plate until full recovery from anesthesia. Sham animals underwent the same procedure except for the puncture of the vessels. At the end of the experiments, mice were intubated, ventilated with 100 % O₂ and isoflurane. Blood was drawn from the right ventricle and O₂ saturation was measured. Only animals with right ventricular O₂ saturation over 90 % were analysed. Hearts were excised and the left ventricle was separated from the atrium and right ventricle. The tissue was shock frozen in liquid nitrogen and stored at −80 °C.

Histology

The hearts were harvested, fixed in 4 % buffered formaldehyde at 4 °C for 24 h, and cryoprotected in 30 % sucrose/PBS overnight before embedding in OCT (Tissue-Tek). Cardiac sections (8 μm) were stained with hae-matoxylin-eosin (H&E). Myocyte cross sectional areas were measured, using NIH Image J software (National Institutes of Health, Bethesda, MD, USA), in sections stained with fluorescein conjugated wheat germ agglutinin (WGA- Alexa Fluor 350, Invitrogen, Carlsbad, CA, USA). At least 100 randomly selected myocytes cut transversely were measured from three animals/group. For immunofluorescence staining, cardiac sections were reacted with primary anti-Desmin (1:200; Sigma-Aldrich, Steinheim, Germany) followed by secondary Alexa Fluor 488 IgG antibody (1:500; Invitrogen). DAPI was used for nuclear staining. Sections were analyzed by reverse microscope fluorescence equipped microscope (BX60; Olympus, Hamburg, Germany).

Echocardiography

2D guided M-mode echocardiography was performed using a VS-VEVO 660/230 high resolution imaging system (VisualSonics, Toronto, Canada). Mice were lightly anesthetized with 2.5 % 2-2-2 Tribromoethanol (Avertin, 0.01 mL/g i.p.) and were allowed to breathe spontaneously. 2D guided M-mode images were recorded in the long-axis view at the left mid-ventricular level. The examiner was blinded towards group assignment.

Reagents

Reagents and their sources were as follows: phosphate buffer saline (PBS) (PAA Laboratories, Cölbe, Germany), sodium carbonate, ammonium bicarbonate, thiourea, dithiothreitol (DTT), urea, trypsin, trifluoroacetic acid (TFA) (Sigma-Aldrich), CHAPS (AppliChem, Darmstadt, Germany), Acetonitril (ACN) (Promochem, Wesel, Germany), Immobilized pH gradient strips (IPG strips), ampholytes, protein assay kit (Bio-Rad, Munich, Germany), protease and phosphatase inhibitor cocktails (Roche, Mannheim, Germany), sodium dodecyl sulfate (SDS) (Serva, Heidelberg, Germany), potassium ferricyanide, Glyceral, sodium thiosulfate (Merck, Darmstadt, Germany), formic acid (BASF, Ludwigshafen, Germany), bromophenol blue (Carl Roth, Karlsruhe, Germany).

Sample preparation for proteome analysis

Left ventricular free wall was homogenized and protein extracted as described earlier [10]. Briefly, tissue samples
were homogenized in buffer (urea 8 mol/L, thiourea 2 mol/L and 2 % CHAPS) at 2600 rpm for 2 min. Total proteins were extracted by sonication on ice three times for 5 s each with nine cycles in Branson Sonifier 250 (G.Heinemann, Schwäbisch Gmünd, Germany). Whole cell lysates were centrifuged at 16,000×g for 15 min at 4 °C. Supernatant was collected in a separate tube and its protein contents was measured by Bradford method using bovine serum albumin as standard and Bio-Rad protein reagent according to manufacturer’s instructions. Tissue proteins were kept at −80 °C until further use.

Two-dimensional gel electrophoresis (2-DE)

Proteins were resolved by a method adopted from Görg et al. [11] with minor modifications. Proteins (110 µg) from sham and shunt samples were diluted in a final volume of 350 µL with rehydration buffer (7 mol/L urea, 2 mol/L thiourea, 4 % CHAPS, 0.2 % ampholyte [pH 3–10], 0.2 % DTT and trace amount of bromophenol blue). Protein samples were applied to IPG (pH 3–10, Linear) in a rehydration tray overlaid with oil and kept overnight at room temperature in the dark for passive rehydration.

The isoelectric focusing (IEF) was performed using a Protean IEF cell (Bio-Rad) under the following conditions: gradient 100 V for 1 h; 500 V for 1 h; 1000 V for 2 h and 8000 V for 2 h with a total of 32,000 volts-h. Following the first dimensional separation, IPG strips were carefully incubated in equilibration buffer 1 (50 mmol/L Tris–HCL [pH 8.8], 6 mol/L urea, 30 % v/v glycerol, 2 % SDS and 10 g/L DTT) for 30 min and then subsequently for 30 min in equilibration buffer 2 (50 mmol/L Tris–HCL [pH 8.8], 6 mol/L urea, 30 % v/v glycerol, 2 % SDS and 40 g/L iodoacetamide). Proteins were then resolved on 12.5 % SDS-PAGE in Protean II chamber (Bio-Rad) with a constant 100 V at 4 °C.

Image analysis

Following the second dimensional separation, gels were silver stained by gold standard method, and scanned using a CanoScan 8400F scanner (Canon, Krefeld, Germany). The gel images were densitometrically analyzed with Delta 2D software 4.0 (Decodon, Greifswald, Germany) [12]. LV free walls from 5 shunt hearts were compared with 5 sham controls. Two independent 2-DE experiments were performed to ensure the reproducibility.

In-gel trypsin digestion of protein spots

The protein spots of interest (differentially regulated proteins) were excised from the gel, which was followed by in-gel digestion according to the method adopted and modified from Shevchenko et al. [13]. In short, gels containing proteins were destained with 100 mmol/L ammonium bicarbonate/acetonitrile (1:1, v/v) initially for 10 min and then until the removal of all dye color. Destaining was followed by drying in vacuum centrifuge (UNIVAPO 150 H; uniEquip, Martinsried, Germany). The proteins in gels were digested with trypsin (10 ng/µL in 100 mmol/L ammonium bicarbonate) for 18 h at 37 °C. Digested peptides were mixed with 50 µL of 0.1 % TFA and sonicated for 30 min. The process was repeated and peptides were extracted with series concentrations of ACN/0.1 % TFA (30 and 60 %). Peptides extracted were concentrated in a vacuum centrifuge and then reconstituted in 0.1 % formic acid.

Quadruple time-of-flight liquid chromatography/mass spectrometry (Q-TOF LC–MS/MS)

QTOF LC–MS/MS analysis of extracted peptides was performed as described earlier [14]. Briefly, the reconstituted peptide samples (1 µL) were loaded for efficient chromatographic separation on a CapLC-System (Waters, Milford, MA, USA). Peptides were injected for sequence analysis into Q-TOF Ultima Global (Micromass, Manchester, UK) mass spectrometer, equipped with a nanoflow ESI Z-spray source in positive ion mode. MS/MS raw data was generated with MassLynx (Micromass), which was converted to Peak list (pkl) files using ProteinLynx Global Server bioinformatics tool (PLUGS; v 2.2; Waters, Manchester, UK). pkl files were searched by MASCOT search engine against SwissProt data bases for peptide matching. Search criteria includes trypsin enzyme for digestion, mass tolerance of ± 0.5 Da and MS/MS tolerance ± 0.5 Da; allowance of up to one missed cleavage peptide and modification of carbamidomethylation and oxidation of methionine.

Functional classification

The predicted functions of the differentially expressed proteins were obtained by PANTHER (http://www.pantherdb.org) and UNIPROT knowledge database (http://www.uniprot.org). Differentially expressed proteins were further explored by Ingenuity Pathways Analysis (IPA, Redwood City, CA) (http://www.ingenuity.com) to reveal differentially regulated signaling networks.

Western blot analysis

Frozen pieces of the left ventricular free wall were thawed on ice in 250 µL of homogenization buffer and homogenized. Protein concentrations of the suspensions were determined and 20 µg of the samples were subjected to SDS-PAGE. Western blotting was carried out according to standard protocols, using antibodies against α-1-antitrypsin, PRDX3, HSPD1, HSPA8, and GAPDH (Santa Cruz Biotechnology, Dallas, USA), COPS4, β-enolase,
MYL2, PTRF, and Ndufs1 (Abcam, Cambridge, UK). For quantification, an enhanced chemiluminescence detection system (Amersham, Braunschweig, Germany) was used according to the manufacturer’s instructions.

**Quantitative real time polymerase chain reaction (qRT-PCR)**

DNA-free total RNA was extracted from left myocardial samples by a standard protocol with the RNasea kit and RNase-free DNAse Set (Qiagen, Hilden, Germany). cDNA synthesis was carried out with iScript cDNA synthesis kit (BioRad, München, Germany) according to manufacturer’s instructions. qRT-PCR was performed on a Biorad iQ-Cycler using SYBR Green Supermix (BioRad). Primer sequences were as follows: *Hprt*: 5′-AGCATCTTG-3′ (sense) and 5′-TCGAAGG-3′ (antisense); *Cox I*: 5′-CAACAGAGTC-3′ (sense) and 5′-CAGCCGATCATAAAGGAGGA-3′ (antisense); *Atp5a1*: 5′-GTTGTCTGT-3′ (sense) and 5′-AGGATAGT-3′ (antisense); *Cox II*: 5′-CAAGACAGATCATAACCTG-3′ (sense) and 5′-CATAACCTG-3′ (antisense).

**Statistical analysis**

The echocardiography and Western blotting groups were analysed using unpaired students t test, with values of P < 0.05 being considered as statistically significant. Fold change of each protein spot between sham and shunt along with their statistical significance (Student’s t test probability) were calculated in the 2-DE gel analyses. Those protein spots having at least 1.5-fold expression changes (P < 0.05) were considered to be statistically significant.

**Results**

**Murine model of short-term volume overload-induced eccentric myocardial hypertrophy**

Volume overload (VO) was induced in wild-type mice by aortocaval shunt. Seven days after shunt, cardiac hypertrophy was evident by an increased left ventricular (LV) weight to tibia length (TL) ratio by ≈31 % (sham vs. shunt: 4.5 ± 0.2 vs. 5.9 ± 0.2; P < 0.05; Fig. 1e), and an increased cardiomyocyte CSA by ≈25 % (Fig. 1a–c, f). Desmin cytoskeleton was not distorted in shunt hearts as indicated by the maintained striations (Fig. 1d).

Representative M-mode echocardiography images demonstrate an increased chamber dimensions observed in shunt mice compared to sham (Fig. 2a). Quantitative analyses showed an eccentric hypertrophy with an increased LV end-diastolic diameter (LVEDD) (sham vs. shunt: 3.23 ± 0.07 vs. 4.23 ± 0.05; +31 %; P < 0.01; Fig. 2b) and unchanged septum wall thickness (sham vs. shunt: 0.98 ± 0.03 vs. 1.01 ± 0.03; P = NS, Fig. 2c). However, the contractile function was preserved (Fractional shortening: sham vs. shunt: 52 ± 2 % vs. 54 ± 1 %, P = NS; Fig. 2d).

**Protein Separation and Q-TOF LC–MS/MS Identification**

Extracts of cardiac lysates were resolved by 2-DE and then stained with silver staining. Twenty five differentially regulated protein spots were clearly and reproducibly resolved when multiple independent samples from sham and shunt were subjected to analysis (Fig. 3a). The 2-DE expressions of three proteins, α-1-antitrypsin, β-enolase and COP9 signalosome complex subunit 4 (COPS4) are shown in gel spot pictures (Fig. 3b).

We used Q-TOF LC–MS/MS to identify each protein. The 25 protein spots, representing 21 different proteins, were then analyzed for differential protein expression. The results of these analyses are shown in Table 1.

**Proteome analysis**

Among these 25 differentially regulated proteins spots, 16 proteins (64 %) were up-regulated in shunt-operated mice, ranging from 2- to 4.7-fold increases. The remaining 9 protein spots (36 %) were down-regulated in shunt-operated mice with levels that were 2.1–4.8-fold lower than in the sham hearts (Table 1). Additional file 1: Table S1 shows the pl, molecular masses, Mascot score, SwissProt accession numbers and MS/MS spectral information.

To better understand the molecular functions and predict the subcellular localizations of the differentially expressed proteins, we searched in the online biological function annotation tool PANTHER (http://www.pantherdb.org) and UNIPROT knowledge database (http://www.uniprot.org). Most of the proteins are identified in the cytoplasm (45 %) and 23 % in nucleus and mitochondrion. Functional classification shows that 44 % (n = 11) of differentially expressed protein spots are involved in mitochondrial metabolism while 24 % (n = 6), 16 % (n = 4) and 16 % (n = 4) of protein spots are associated with cytoskeleton, metabolism and other not specified functions, respectively (Table 1).

We identified 7 differentially expressed electron transport chain (ETC) subunits. Of these, five ETC subunits (≈72 %), specifically four subunits of complex V and one subunit of complex III, were significantly more abundant (Table 1). To investigate the level of regulation of mitochondrial protein expression in VO, we performed real time PCR for mRNAs representing nuclear and mtDNA-encoded mitochondrial proteins. Neither mRNAs for the mtDNA gene (*Cox I, Cox II, Uqcrcl*), nor chromosomal
genes (Atp5a1) encoding proteins were differentially expressed by VO (Fig. 4a).

**Validation by western blotting**
We selected some differentially expressed proteins identified by 2-DE for immunoblotting. Consistently shunt induced-VO resulted in significant increased expression of 60 kDa heat shock protein, mitochondrial (HSPD1), Polymerase I and transcript release factor (PTRF) and ß-enolase (Fig. 4b, c), and marked decreased expression of Thioredoxin-dependent peroxide reductase, mitochondrial (PRDX3), Myosin regulatory light chain 2, ventricular/cardiac muscle isoform (MYL2), NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial (Ndufs1), Heat shock cognate 71 kDa protein (HSPA8) and α-1-antitrypsin (Fig. 4b, d). Signalosome complex subunit 4 (COPS4) signalosome complex subunit 4 (COPS4) showed a trend towards an increased expression in shunt mice but did not reach statistical significance (P = 0.09; Fig. 4b, c).

**Protein networks involved in short-term preload**
Ingenuity pathways analysis (IPA) software was selected to generate systematic network analysis of the differentially expressed proteins to elucidate integrated signaling pathways under VO. Counterparts of all these protein genes were imported to the IPA module. The generated network was attributed to the functions of energy production, nucleic acid metabolism, small molecule biochemistry, and has 35 genes (the maximum number of genes per network), among which 19 differential protein genes are involved in this network (score = 56, highly significant) (Fig. 5).

**Discussion**
Proteomics provides a powerful experimental approach for observing the global changes in protein expression (level and profile) in cells, tissues or whole organs, in both physiological and pathological conditions. Several studies have examined differences in protein expression developed in different subcellular compartments of hearts and alteration in the protein expression due to afterload-induced cardiac hypertrophy [15, 16]. However, little is known about the alterations induced by preload. Thus, we have chosen a proteomic approach in a mouse model of VO-induced myocardial hypertrophy by aorto-caval shunt operation and report proteomic changes after 1 week.

As predicted, VO in our murine model resulted in LV hypertrophy and LV dilatation with maintained LV function. Upon comparison between shunt and sham controls, we obtained 25 differentially displayed spots, corresponding to 21 unique proteins. It has to be highlighted that the number of spots is different from the number of the identified unique proteins, as multiple spots are generated by the same protein likely representing post-translational modifications of the protein. We found preload-induced expression changes of the following functional protein clusters: (1) myofilaments and intermediate filaments, (2) energy metabolism, and (3) other interesting proteins like α-1-antitrypsin and PTRF.

**Myofilaments and intermediate filaments**
In agreement with previous studies from other cardiac hypertrophy models [17], we found an up-regulation of
contractile proteins like actin and myosin VI. We also found a down-regulation of the myosin regulatory light chain 2 (MYL2). MYL2 is a cardiac-specific protein that dimerizes with cardiac myosin beta heavy chain, and its phosphorylation by \( \text{Ca}^{2+} \) triggers cardiac contraction. MYL2 mutations are associated with heart failure and familial hypertrophic cardiomyopathy [18, 19]. Li et al. [20] found a correlation between decreased MYL2 protein level and the stage of heart failure, but the analyzed samples were from the right atrium and therefore a regulation in the ventricle has not been described before. But the reduced expression of the measured spot could also be due to reduced phosphorylation. Decreased phosphorylation of MYL2 is associated with hypertrophy and fibrosis [21]. Therefore a change in MYL2 expression or phosphorylation might contribute to hypertrophy and over a longer time to heart failure development.

**Energy metabolism**

Also not surprisingly, proteins of the energy metabolism were differentially expressed after VO induction. We found an up-regulation of \( \beta \)-enolase protein, which mediates the penultimate step of glycolysis, converting 2-phosphoglycerate to phosphoenolpyruvate, and plays an important role in glycolytic energy production. Increased expression is likely to cope with the increased metabolic demands. Lactate dehydrogenase was significantly down-regulated, implying a shift to oxidative metabolism. Consistently, we identified five abundantly expressed ETC subunits, suggesting enhanced oxidative mitochondrial machinery in VO. Interestingly gene expression levels of mitochondrial Complex 1 (\( \text{Cox I} \) and \( \text{Cox II} \)), Complex III (\( \text{Uqcrcl} \)) and Complex V (\( \text{Atp5a1} \)) were not differentially expressed after shunt suggesting that the VO affects the expression of mitochondrial proteins at a post-transcriptional level. Previously it was reported that post-translational modification largely affects the mitochondrial protein levels [22–24].

Unpublished results from our group show that in pressure overload the regulation of mitochondrial proteins is nearly absent after 1 week. Moreover, several reports demonstrated a substantial defect in cardiac oxidative capacity and ETC subunits in pressure overload-induced heart failure [25, 26]. Because it is known that energy deficiency may contribute to heart failure [27, 28], enhancing respiratory chain machinery may prove to be beneficial in heart failure as an attempt to use an ‘oxygen-efficient’ energy substrate for ATP synthesis [29]. Moreover, the up-regulation of ATP synthase subunit alpha protein fits to our previously published in vitro results [17]. There we could show that preload leads to an
Fig. 3 Differentially expressed protein spots in mouse myocardial tissue at 1 week of volume overload. **a** Total protein lysates from sham and shunt myocardium were resolved by 2-DE gel followed by silver staining. Encircled differentially expressed protein spots were identified using Q-TOF mass spectrometer. **b** Representative areas in the silver-stained gels show differential expression of α-1-antitrypsin, β-enolase and COP9 signalosome complex subunit 4 (COPS4) along with their densitometry measurement in sham and shunt. Values are mean ± SEM; n = 5/group; analysis per heart in duplicate.
increase in metabolic proteins in a model of rabbit isolated cardiac muscle strips.

**Extracellular matrix (ECM) remodeling**

Although cardiomyocytes constitute 70 % of the cardiac tissue mass, they represent only about 30 % of the cell population in the heart. The other predominant cell type is the fibroblast [30]. Fibroblasts actively synthesize and secrete ECM and contribute to the propagation of the electric signals that orchestrate cardiac contraction [31]. The remodeling of ECM proteins seems to be one of the important mechanisms for the early adaptive dilatation of the heart after induction of VO, but persistent proteolytic activity might also be a mechanism for the progression to heart failure [32]. Alpha-1-antitrypsin, a member of the serine protease inhibitor family with anti-inflammatory and immunomodulatory properties [33], was recently reported to have a cytoprotective role in the endothelial cells exposed to ischemia reperfusion injury [34]. Here we found that α-1-antitrypsin was significantly down-regulated. This would lead to a higher elastin degradation rate in the heart. These results fit to studies from Zheng et al. [32] and Stewart et al. [35] showing an increased degradation of the ECM after induction of VO.

**Polymersase I and transcript release factor protein**

Furthermore, we demonstrated that PTRF was up-regulated in VO. PTRF protein is involved in the transcription release of pre-ribosomal RNA and polymersase I from the DNA and regulates rRNA transcription by promoting the dissociation of transcription complexes and the reinitiation of polymersase I [36]. PTRF is localized in the caveole of various cell types, including myocytes, endothelial cells and fibroblasts [37, 38], and that insulin treatment can induce its nuclear translocation [39]. The increase in the protein expression of PTRF in the VO model might be related to an increase in cell length [5]. Or it can be speculated that the number of caveolae might be changed.

### Table 1 Molecular functions of differentially expressed proteins spots in shunt compared to sham

| Protein Spot number | Average sham | Average shunt | T test | Regulation (%) |
|---------------------|--------------|---------------|--------|----------------|
| Cytoskeletal and contractile proteins | | | | |
| Actin, aortic smooth muscle | 5 | 0.266 | 0.126 | 0.007 | −53 |
| Actin, cytoplasmic | 22 | 0.085 | 0.188 | 0.030 | 121 |
| Myosin-6 | 20 | 0.010 | 0.026 | 0.029 | 167 |
| Myosin regulatory light chain 2, ventricular/cardiac muscle isoform | 14 | 0.743 | 0.347 | 0.021 | −53 |
| Tropomyosin alpha-1 chain | 21 | 0.037 | 0.097 | 0.030 | 162 |
| Tubulin beta-2C chain | 4 | 0.010 | 0.026 | 0.006 | 166 |
| Metabolism | | | | |
| β-enolase | 3 | 0.052 | 0.187 | 0.005 | 263 |
| β-enolase | 34 | 0.0057 | 0.211 | 0.0047 | 271 |
| Delta-aminolevulinic acid dehydratase | 25 | 0.018 | 0.121 | 0.037 | 571 |
| L-lactate dehydrogenase B chain | 13 | 0.059 | 0.028 | 0.018 | −52 |
| Mitochondrial proteins | | | | |
| ATP synthase subunit alpha, mitochondrial (Complex V) | 30 | 0.0297 | 0.018 | 0.0041 | 108 |
| ATP synthase subunit d, mitochondrial (Complex V) | 31 | 0.0266 | 0.0068 | 0.0042 | −74 |
| ATP synthase subunit alpha, mitochondrial (Complex V) | 33 | 0.0045 | 0.0099 | 0.0047 | 119 |
| ATP synthase subunit beta (Complex V) | 12 | 0.0069 | 0.0147 | 0.0023 | 115 |
| ATP synthase subunit beta, mitochondrial (Complex V) | 38 | 0.0044 | 0.0086 | 0.0018 | 96 |
| Cytochrome b-c1 complex subunit 1 (Complex III) | 7 | 0.0089 | 0.0027 | 0.0012 | −69 |
| Cytochrome b-c1 complex subunit 1, mitochondrial (Complex III) | 32 | 0.0005 | 0.0025 | 0.0043 | 368 |
| Electron transfer flavoprotein subunit beta | 8 | 0.0094 | 0.0249 | 0.0015 | 164 |
| 60 kDa heat shock protein, mitochondrial | 24 | 0.0041 | 0.0081 | 0.0034 | 97 |
| NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial | 16 | 0.0146 | 0.0071 | 0.0025 | −51 |
| Thioredoxin-dependent peroxide reductase, mitochondrial | 35 | 0.0016 | 0.0004 | 0.0048 | −74 |
| Others | | | | |
| α-1-antitrypsin 1-2 | 1 | 0.0813 | 0.0345 | 0.0002 | −58 |
| COP9 signalosome complex subunit 4 | 18 | 0.0049 | 0.0113 | 0.0026 | 132 |
| Heat shock cognate 71 kDa protein | 11 | 0.0061 | 0.0013 | 0.0039 | −79 |
| Polymerase I and transcript release factor | 28 | 0.0304 | 0.0657 | 0.0039 | 116 |
Fig. 4 Validation of proteomics data. a Real time of mtDNA gene Cox I, Cox II, Uqrc1 and nuclear genes Atp5a1. b Representative Western blots showing change in the expression of 60 kDa heat shock protein, mitochondrial (HSPD1), Polymerase I and transcript release factor (PTRF), 6-enolase (Eno3), COP9 signalosome complex subunit 4 (COP54), Thioredoxin-dependent peroxide reductase, mitochondrial (PRDX3), Myosin regulatory light chain 2, ventricular/cardiac muscle isoform (MYL2), NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial (Ndufs1), Heat shock cognate 71 kDa protein (HSPA8), and α-1-antitrypsin in respective experimental groups. c, d Graphs showing relative band intensity as revealed by Western blot analyses. Values are mean ± SEM; n = 4–5/group; analysis per heart in duplicate; *P < 0.05 vs. sham.
in VO hypertrophy. Mutations in the PTRF gene lead to fatal cardiac arrhythmia and long-QT-syndrome [40], indicating a relevant role in the heart.

**Analysis of the preload interaction network**
Cardiovascular diseases are complicated diseases that are controlled by complex regulation network. The customized pathways disclosed by IPA have important implications for the understanding of the pathogenesis of favorable remodeling induced by preload. It is noteworthy that most of the proteins identified are interconnected on the same network that primarily involves structural and metabolic proteins and enzymes involved in energy metabolism and nucleic acid metabolism.

**Potential limitation**
The proteome we map is a mixture of proteins not only from cardiomyocytes but also from other cell types present in the heart, including fibroblasts, endothelial cells, and smooth muscle cells. Because the heart functions as an organ, and not as isolated cells, it can be viewed as an advantage to capture the proteome dynamics of the
whole heart, rather than restricted only to the cardiomyocytes. Our rationale for examining the entire heart, then, was that we wanted to map the proteomic changes in a state as close as possible to that in vivo, which would be impossible upon cardiomyocytes isolation by enzymatic dissociation.

The nature of proteomic technique makes certain potentially relevant proteins difficult to interrogate, and their absence among the proteins identified in our study does not exclude a potential role in preload-induced eccentric remodeling. Ion channel proteins show relatively low-level expression compared to structural, contractile and metabolic proteins, explaining the lack of ion channel subunits among the differentially expressed proteins identified.

In the current study we have not studied the diastolic function, but previously we and others reported an impaired diastolic function in the mouse model upon exposure to VO owing to increased titin stiffness [41, 42].

Conclusions
In the present study we concluded that the preload-induced eccentric cardiac hypertrophy leads to an adaptive change in the proteome with up-regulation of some mitochondrial and contractile proteins. Furthermore down-regulation of α-1-antitrypsin might contribute to the ECM remodeling leading to early dilatation. Further exploration of these proteomic data will contribute to understanding the pathogenesis of VO induced-myocardial remodeling. Besides some of the proteins found to be differentially abundant may be candidate biomarkers for diagnosis and prognosis of VO-induced myocardial remodeling.

Additional file

Additional file 1: Table S1. MS/MS analysis table for identified proteins.

Authors’ contributions

The authors have made the following declarations about their contributions. Conceived and designed the experiments: GH, KT. Performed the experiments: BAM, ARA, MS, MQ. Analysed the data: BAM, PS, KT. Contributed reagents/materials/analysis tools: SK, DL. Wrote the paper: BAM, GH, KT. All authors read and approved the final manuscript.

Author details
1 Department of Cardiology and Pneumology, University Medical Center, Goettingen, Germany. 2 DZHK (German Centre for Cardiovascular Research), Partner Site Goettingen, Germany. 3 Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Mansoura University, Mansoura, Egypt. 4 Institute of Clinical Chemistry/UMG-Laboratories, University Medical Center, Goettingen, Germany. 5 Department of Microbiology, Kohat University of Science and Technology, Kohat, Pakistan. 6 Abteilung Kardiologie und Pneumologie, Universitätsmedizin Göttingen, Robert-Koch-Str 40, 37075 Göttingen, Germany.

Acknowledgements
We thank Sabrina Koszewa for excellent technical support.

Competing interests
The authors declare that they have no competing interests.

Grant
This work was supported the German Research Foundation (SFB1002 to K.T. and G.H.).

Received: 2 December 2015 Accepted: 7 May 2016 Published online: 27 May 2016

References

1. Grossman W, Jones D, McLaurin LP. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest. 1975;56:56–64.
2. Linke WA. Sense and stretchability: the role of titin and titin-associated proteins in myocardial stress-sensing and mechanical dysfunction. Cardiovasc Res. 2008;77:637–48.
3. von Lewinski D, Stumme B, Falika F, Luers C, Pieske B. Functional relevance of the stretch-dependent slow force response in failing human myocardium. Circ Res. 2004;94:1392–8.
4. Norton JM. Toward consistent definitions for preload and afterload. Adv Physiol Educ. 2001;25:53–61.
5. Toischer K, Rokita AG, Unsold B, Zhu W, Karagias G, Sossalla S, et al. Differential cardiac remodeling in preload versus afterload. Circulation. 2010;122:993–1003.
6. Backs J, Backs T, Neef S, Kreusser MM, Lehmann HT, Patrick DM, et al. The delta isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodeling after pressure overload. Proc Natl Acad Sci USA. 2009;106:2342–7.
7. Ling H, Zhang T, Pereira L, Cheng H, Gu Y, et al.Requirement for Ca2+/calmodulin-dependent kinase II in the transition from pressure overload-induced cardiomyohypertrophy to heart failure in mice. J Clin Invest. 2009;119:1239–49.
8. Köglér H, Schott P, Toischer K, Milting H, Van PN, Kohlihasa M, et al. Relevance of brain natriuretic peptide in preload-dependent regulation of cardiac sarcoplasmic reticulum Ca2+-ATPase expression. Circulation. 2006;113:2724–32.
9. Toischer K, Köglér H, Tenderich G, Grebe C, Seidler T, Van PN, et al. Elevated afterload, neuroendocrine stimulation, and human heart failure increase BNP levels and inhibit preload-dependent SERCA upregulation. Circ Heart Fail. 2008;1:265–71.
10. Nishtala K, Phong TQ, Steil L, Sauter M, Salazar MG, Kandolf R, et al. Proteomic analyses of age related changes in A.BY/Snu mouse hearts. Proteome Sci. 2013;11:29.
11. Gorg A, Obermaier C, Boguth G, Harder A, Scheibe B, Wildgruber R, et al. The current state of two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis. 2000;21:1037–53.
12. Luhn S, Berth M, Hecker M, Bernhardt J. Using standard positions and image fusion to create proteome maps from collections of two-dimensional gel electrophoresis images. Proteomics. 2003;3:1117–27.
13. Stevchenko A, Wilm M, Vorm O, Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem. 1996;68:850–4.
14. Qasim M, Rahman H, Oellerich M, Asif AR. Differential proteome analysis of human embryonic kidney cell line (HEK-293) following mycopenic acid treatment. Proteome Sci. 2011;9:57.
15. Dai DF, Hsieh EJ, Liu Y, Chen T, Beyer RP, Chin MT, et al. Mitochondrial proteome remodelling in pressure overload-induced heart failure: the role of mitochondrial oxidative stress. Cardiovasc Res. 2012;93:79–88.
16. Dai DF, Hsieh EJ, Chen T, Menendez LG, Basisty NB, Tsai L, et al. Global proteomics and pathway analysis of pressure-overload-induced heart failure and its attenuation by mitochondrial-targeted peptides. Circ Heart Fail. 2013;6:1067–76.
17. Schott P, Asif AR, Graf C, Toischer K, Hasenfuss G, Köglér H. Myocardial adaptation of energy metabolism to elevated preload depends on calcineurin activity: a proteomic approach. Basic Res Cardiol. 2008;103:232–43.
18. Richard P, Charron P, Carrier L, Ledeuil C, Cheav T, Pichereau C, et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum
of mutations, and implications for a molecular diagnosis strategy. Circulation. 2003;107:2227–32.

19. Kabaeva ZT, Perrot A, Wolter B, Dietz R, Cardim N, Correa JM, et al. Systematic analysis of the regulatory and essential myosin light chain genes: genetic variants and mutations in hypertrophic cardiomyopathy. Eur J Hum Genet. 2002;10:741–8.

20. Li Y, Wu G, Tang Q, Huang C, Jiang H, Shi L, et al. Slow cardiac myosin regulatory light chain 2 (MYL2) was down-expressed in chronic heart failure patients. Clin Cardiol. 2011;34:30–4.

21. Ding P, Huang J, Battiprolu PK, Hill JA, Kamm KE, Stull JT. Cardiac myosin light chain kinase is necessary for myosin regulatory light chain phosphorylation and cardia performance in vivo. J Biol Chem. 2010;285:40819–29.

22. Tian Q, Stepaniants SB, Mao M, Weng L, Feetham MC, Doyle MJ, et al. Integrated genomic and proteomic analyses of gene expression in mammalian cells. Mol Cell Proteom. 2004;3:960–9.

23. Margineantu DH, Emerson CB, Diaz D, Hockenbery DM. Hsp90 inhibitory factors decrease mitochondrial protein turnover. PLoS ONE. 2007;2:e1066.

24. Kadenbach B, Hüttemann M. The subunit composition and function of mammalian cytochrome c oxidase. Mitochondrion. 2015;24:64–76.

25. Bugger H, Schwarzer M, Chen D, Schrepper A, Amorim PA, Schoepe M, et al. Proteomic remodelling of mitochondrial oxidative pathways in pressure overload-induced heart failure. Cardiovasc Res. 2010;85:376–84.

26. Zhabyeyev P, Gandhi M, Mori J, Basu R, Kassin Z, Clanachan A, et al. Pressure-overload induced heart failure induces a selective reduction in glucose oxidation at physiological afterload. Cardiovasc Res. 2013;97:676–85.

27. Weekes J, Wheeler CH, Yan JX, Weil J, Eschenhagen T, Scholtysik G, et al. Bovine dilated cardiomyopathy: proteomic analysis of an animal model. Biochim Biophys Acta. 2001;1519:232–43.

28. Sakai J, Ishikawa H, Satoh H, Yamamoto S, Kojima S, Kanaoka M. Glucose oxidation at physiological afterload. Cardiovasc Res. 2005;67:104–14.

29. Ardehali H, Sabbah HN, Burke MA, Sarma S, Liu PP, Cleland JG, et al. Targeting myocardial substrate metabolism in heart failure potential for new therapies. Eur J Heart Fail. 2012;14:120–2.

30. Baudino TA, Carver W, Giles W, Borg TK. Cardiac fibroblasts: friend or foe? Am J Physiol Heart Circ Physiol. 2009;296:H1015–26.

31. Kohl P, Camelliti P, Burton FL, Smith GL. Electrical coupling of fibroblasts and myocytes: relevance for cardiac propagation. J Electrocardiol. 2009;39:45–50.

32. Zheng J, Chen Y, Pat B, Dell’Italia LA, Tillson M, Dillon AR, et al. Microarray identifies extensive downregulation of noncollagen extracellular matrix and profibrotic growth factor genes in chronic isolated mitral regurgitation in the dog. Circulation. 2009;119:2086–95.

33. Janciauskiene SM, Bals R, Koczulla R, Vogelmeier C, Kohnlein T, Welte T. The discovery of 01-antitrypsin and its role in health and disease. Respir Med. 2011;105:1129–39.

34. Feng Y, Hu L, Xu Q, Yuan H, Ba L, He Y, et al. Cytoprotective role of alpha-1 antitrypsin in vascular endothelial cell under hypoxia/reoxygenation condition. J Cardiovasc Pharmacol. 2015;66:96–107.

35. Stewart JA Jr, Wei CC, Brower GL, Rynders PE, Hankes GH, Dillon AR, et al. Cardiac mast cell- and chymase-mediated matrix metalloproteinase activity and left ventricular remodeling in mitral regurgitation in the dog. J Mol Cell Cardiol. 2003;35:311–9.

36. Low JY, Nicholson HD. Emerging role of polymerase-1 and transcript release factor (PTRF/Cavin-1) in health and disease. Cell Tissue Res. 2014;357:505–13.

37. Hill MM, Bastiani M, Luetterforst R, Kirkham M, Kirkham A, Nixon SJ, et al. PTRF-Cavin, a conserved cytoplasmic protein required for caveola formation and function. Cell. 2008;132:113–24.

38. Bastiani M, Liu L, Hill MM, Jedrychowski MR, Nixon SJ, Lo HP, et al. MURC/Cavin-4 and cavin family members form tissue-specific caveolar complexes. J Cell Biol. 2009;185:1259–73.

39. Zhu H, Lin P, De G, Choi KH, Takeshima H, Weisleder N, et al. Polymerase transcriptase release factor (PTRF) anchors MGS3 protein to cell injury site for initiation of membrane repair. J Biol Chem. 2011;286:12820–4.

40. Rajab A, Straub V, McCann LJ, Seelow D, Varon R, Barresi R, et al. Fatal cardiac arrhythmia and long-QT syndrome in a new form of congenital generalized lipodystrophy with muscle rippling (CGL4) due to PTRF/CAVIN mutations. PLoS Genet. 2010;6:e1000874.

41. Mohamed BA, Schnelle M, Khadjeh S, Libk D, Herwig M, Linke WA, et al. Molecular and structural transition mechanisms in long-term volume overload. Eur J Heart Fail. 2015. doi:10.1002/ejhf.465.

42. Hutchinson KR, Saripalli C, Chung CS, Granzier H. Increased myocardial stiffness due to cardiac titin isoform switching in a mouse model of volume overload limits eccentric remodeling. J Mol Cell Cardiol. 2015;79:104–14.